Home›Stock Screener›Lyka Labs

Lyka Labs Share Price Today | Stock Price & Lyka Labs Share Screener

LYKALABS Pharmaceuticals
Live Share Price NSE
₹73.95
▲ 0.91 (1.25%)
2026-06-30 00:00:00
Live Share Price BSE
₹78.36
▼ -4.12 (-5.00%)
2026-10-05 00:00:00

As of June 30, 2026, the live Lyka Labs share price (NSE: LYKALABS) is ₹73.95 on NSE and ₹78.36 on BSE, up 1.25% from the previous close, with shares trading between ₹71.00 and ₹74.80 in today's trading session, and a 52-week range of ₹44.95–₹96.92. Check LYKALABS price range for the annual price range and momentum. Use the Lyka Labs stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Lyka Labs opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹29 and net income of ₹-8, with EBITDA of ₹-6, an operating margin of -23.0% and a profit margin of -27.6%.

Lyka Labs Market Cap ₹294.83 Cr.
LYKALABS P/E Ratio (TTM) -32.37
Lyka Labs P/B Ratio 3.28
EPS (TTM) ₹-2.81
Dividend Yield -
Debt to Equity 0.44
LYKALABS 52 Week High ₹96.92
Lyka Labs 52 Week Low ₹44.95
Operating Margin -23.00%
Profit Margin -27.59%
LYKALABS Revenue (TTM) ₹29.00
EBITDA ₹-6.00
Net Income ₹-8.00
Total Assets ₹175.00
Total Equity ₹91.00

Lyka Labs Share Price Chart

Track the current stock price of Lyka Labs with an interactive chart. Analyse LYKALABS share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Lyka Labs stock quote in one place.

The quote of ₹73.95 sits between the 52-week low of ₹44.95 and the 52-week high of ₹96.92, and the latest session moved 1.25% from the previous close.

Lyka Labs Company Profile - Fundamental Screener

Screen Lyka Labs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for LYKALABS shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE933A01014.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

ISIN INE933A01014

Lyka Labs Balance Sheet Screener

Screen LYKALABS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹175, down from ₹176 in 2025.

Latest statistics put total assets at ₹175 and shareholder funds at ₹91, with a leverage ratio of 0.44.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 175 176 157 152 186 190 200 216 229 252
Current Assets 63 67 51 44 52 29 36 35 49 63
Fixed Assets 87 85 58 68 94 98 105 108 116 133

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 30 26 51 73 73 165 149 85 9 42
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 91 104 68 46 14 -25 -15 46 53 45
Share Capital 36 36 33 31 29 29 29 28 28 22
Reserves & Surplus 57 69 26 -3 -15 -55 -43 14 21 16

Lyka Labs Income Statement Screener - Profit & Revenue Analysis

Screen Lyka Labs income statement and profit fundamentals. Analyze LYKALABS quarterly results. Lyka Labs reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹29 and net profit was ₹-8, equal to earnings per unit of ₹-2.10, at an operating margin of -23%.

In that period expenses were ₹35, interest cost ₹1 and tax ₹-1. The next period listed, 2026-Jun, shows revenue of ₹43 and net profit of ₹2.

Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec 2022-Mar

Revenue and Expenses

Revenue 29 43 34 34 38 32 28 31 41 35 23 23 28 33 36
Expenses 35 38 29 29 39 29 26 26 36 29 19 20 24 26 25

Operating Costs and Margins

EBITDA -6 5 5 4 -2 3 2 4 5 6 3 3 4 7 10
Operating Profit % -23.00% 11.00% 12.00% 11.00% -7.00% 5.00% 7.00% 12.00% 12.00% 15.00% 13.00% 12.00% 13.00% 21.00% 28.00%
Depreciation 2 2 1 2 2 2 3 2 2 2 4 4 4 3 10
Interest 1 1 1 1 1 1 1 1 1 1 3 1 1 1 3

Profit and Earnings

Profit Before Tax -9 2 3 1 -4 0 -2 2 3 4 -3 -2 -1 3 -2
Tax -1 0 1 0 -1 0 1 1 1 1 0 0 0 2 13
Net Profit -8 2 2 1 -3 0 -2 1 2 3 -3 -2 -1 2 -15
EPS -2.10 0.57 0.49 0.25 -0.94 0.00 -3.83 0.40 0.58 0.75 -1.05 -0.57 -0.15 0.53 -5.26

Lyka Labs Cash Flow Screener - Liquidity Fundamentals

Screen LYKALABS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹5.

Over the same period, investing activities used ₹9 and financing activities provided ₹4.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 5 2 2 9 79 9 5 27 11 31
Investing Activities -9 -12 -10 7 -6 0 0 -4 -3 -13

Financing and Net Cash

Financing Activities 4 5 2 -22 -63 -12 3 -23 -10 -19
Net Cash Flow 0 -5 -6 -5 10 -3 9 -1 -3 0

Lyka Labs Shareholding Pattern Screener

See Lyka Labs shareholding pattern with promoter, FII, and DII holdings. Check Lyka Labs promoter holding and ownership changes for LYKALABS on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 58.16%, foreign institutions 0.29%, domestic institutions 0.67% and the public 31.06%, spread across 26,727 shareholders.

The shareholder count was 26,727 in 2026-Mar, compared with 29,369 in 2026-Jun.

Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Apr

Promoter Holding

Promoter Holding 58.16% 58.45% 58.16% 58.16% 58.16% 58.16% 54.81% 58.10%

Institutional Investors

FII Holding 0.29% 0.17% 0.23% 0.16% 0.18% 0.17% 0.17% 0.16%
DII Holding 0.67% 0.66% 0.67% 0.67% 0.67% 0.67% 0.88% 0.82%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 31.06% 31.18% 31.18% 31.41% 31.52% 31.42% 33.90% 31.48%
Other Holding 9.82% 9.54% 9.76% 9.61% 9.48% 9.57% 10.23% 9.44%
Shareholder Count 26,727 29,369 28,472 28,189 27,743 27,155 25,717 25,699

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Lyka Labs. Lyka Labs dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Lyka Labs.

Lyka Labs Stock Index Membership - Nifty & Sensex

See which indices include Lyka Labs stock. Check LYKALABS index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Lyka Labs is not part of any tracked indices.
Only major market indices are tracked in our system.

Lyka Labs Market Events Screener - Corporate Actions

Get Lyka Labs corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Lyka Labs stock events that may affect LYKALABS share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated August 10, 2026, with a record date of August 10, 2026.

It is followed by Annual General Meeting dated August 10, 2026 and Merger - Demerger dated June 4, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-08-10 2026-08-10 Quarterly Result Announcement NA 7.52%
2026-08-10 2026-08-10 Annual General Meeting NA 9.51%
2026-06-04 2026-06-04 Merger - Demerger 100:23 0.00%
2026-05-25 2026-05-25 Quarterly Result Announcement NA -3.64%
2026-01-29 2026-01-29 Quarterly Result Announcement NA -3.07%
2025-11-12 2025-11-12 Quarterly Result Announcement NA -3.01%
2025-08-01 2025-08-01 Annual General Meeting NA 4.21%
2025-08-01 2025-08-01 Quarterly Result Announcement NA 1.70%
2025-05-26 2025-05-26 Quarterly Result Announcement NA 5.18%
2025-03-04 2025-03-04 Extraordinary General Meeting NA -30.25%
2025-02-04 2025-02-04 Quarterly Result Announcement NA -7.74%
2024-11-12 2024-11-12 Quarterly Result Announcement NA 2.19%
2024-08-09 2024-08-09 Annual General Meeting NA 2.08%
2024-02-20 2024-02-20 Extraordinary General Meeting NA 9.92%
2023-02-17 2023-02-17 Extraordinary General Meeting NA -16.64%

Lyka Labs Competitors Screener - Peer Stocks Comparison

Screen LYKALABS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 432,120 36.04 61,674 12.69% 11,565 36.68
Divis Laboratories 245,532 84.24 11,067 13.95% 2,568 51.70
Torrent Pharmaceuticals 181,333 84.71 13,886 20.34% 2,138 41.12
Zydus Life Science 114,284 25.27 27,658 17.64% 5,026 47.64
Cipla 108,576 32.50 29,045 2.24% 3,870 34.78
Laurus Labs 107,198 98.20 6,868 22.01% 890 58.70
Mankind Pharma 104,707 50.04 14,636 14.85% 1,938 61.75
Dr Reddys Laboratories 100,679 32.41 35,059 3.90% 4,158 53.84
Aurobindo Pharma 96,479 25.84 34,145 5.56% 3,503 50.30
Lupin 92,885 16.82 29,039 26.75% 5,356 31.59

Lyka Labs Company Announcements - News & Reports Screener

Screen LYKALABS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated September 27, 2026.

The next most recent announcements are dated August 12, 2026 and August 11, 2026.

Date Update Actions
2026-09-27 Closure of Trading Window -
2026-08-12 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-11 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-08-11 Revised Press Release On Unaudited Financial Results For The Q1 June 2026 -
2026-08-10 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-08-10 Press Release For Unaudited Financial Results Of Q1 June 2026 -
2026-08-10 Financial Results For June 2026 -
2026-08-10 Board Meeting Outcome for Outcome Of The Board Meeting Dated 10Th August 2026 -
2026-07-24 Board Meeting Intimation for Board Meeting To Be Held On Monday 10Th August 2026 -
2026-07-20 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-07-17 47Th AGM Of The Company To Be Held On Monday 10Th August 2026 At 12.30 PM Through Video Conferencing -
2026-07-17 Letter Sent To Shareholders -
2026-07-17 Reg. 34 (1) Annual Report. -
2026-07-17 Intimation Of Annual General Meeting To Be Held On 10Th August 2026 -
2026-07-10 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-07-08 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-06-30 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-06-30 Disclosure Under Regulation 7 (2) Read With Regulation 6(2) - Continual Disclosure Of SEBI (Prohibition Of Insider Trading) Regulations 2015 -
2026-06-29 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-06-26 Disclosure Under Regulation 7 (2) Read With Regulation 6(2) - Continual Disclosure Of SEBI (Prohibition Of Insider Trading) Regulations 2015 -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹73.95, within a 52-week range of ₹44.95 to ₹96.92. The P/E ratio is -32.37 and the P/B ratio is 3.28, with earnings per unit of ₹-2.81. Market capitalisation stands at ₹294.83 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.